In vivo efficacy and pharmacokinetics of biapenem in a murine model of ventilator-associated pneumonia with Pseudomonasaeruginosa

Journal of Infection and Chemotherapy

Volumn 18, Issue 4, 2012, Pages 472-478

  Yamada, Koichi ^a   Yamamoto, Yoshihiro ^a   Yanagihara, Katsunori ^a   Araki, Nobuko ^a   Harada, Yosuke ^a   Morinaga, Yoshitomo ^a   Izumikawa, Koichi ^a   Kakeya, Hiroshi ^a   Hasegawa, Hiroo ^a   Kohno, Shigeru ^a   Kamihira, Shimeru ^a  

^a NAGASAKI UNIVERSITY   (Japan)

Author keywords

Biapenem; Pseudomonas aeruginosa; Ventilator associated pneumonia

Indexed keywords

BIAPENEM; CILASTATIN; MEROPENEM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG TISSUE LEVEL; HISTOPATHOLOGY; IN VIVO STUDY; LUNG HEMORRHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PSEUDOMONAS AERUGINOSA; SURVIVAL TIME; VENTILATOR ASSOCIATED PNEUMONIA;

EID: 84865134801     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0359-2     Document Type: Article

References (24)

1. J Chastre JY Fagon 2000 Ventilator-associated pneumonia Am J Respir Crit Care Med 65 867 903
2. DM Livemore 2002 Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare? ClinInfect Dis 34 634 640 10.1086/338782 (Pubitemid 34165326)
3. J Van Eldere 2003 Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocominal infectionsJ Antimicrob Chemother 51 347 352 12562701 10.1093/jac/dkg102 (Pubitemid 36231155)
4. American Thoracic Society 2005 Guidelines for the management of adults with hospital-acquired, ventilator-associated,and healthcare-associated pneumonia Am J Respir Crit Care Med 171 388 416 10.1164/rccm.200405-644ST (Pubitemid 40227463)
5. AA El Sohl A Alhajhusain 2009 Update on the treatment of Pseudomonas aeruginosa pneumonia J Antimicrob Chemother 64229 238 10.1093/jac/dkp201
6. K Ubukata N Chiba R Kobayashi 2002 Comparison of in vitro activity of biapenem with other antimicrobial agents againstclinical isolates of Pseudomonas aeruginosa Chemother Jpn 50 1 10 1:CAS:528:DC%2BD38XhsVCksb8%3D (Pubitemid 34202040)
7. G Bonfiglio G Maccarone ML Mezzatesta A Privitera V Carciotto M Santagati, et al. 1997 In vitro activity of biapenemagainst recent gram-negative, gram-positive clinical isolates Chemotherapy 43 393 9395852 10.1159/0002395971:CAS:528:DyaK2sXntlartbY%3D
8. K Gomi S Fujimura K Fuse H Takane Y Nakao Y Kariya, et al. 2010 Antibacterial activity of carbapenems against clinicalisolates of respiratory bacterial pathogens in the northeastern region of Japan in 2007 J Infect Chemother 17 200 20620839026 10.1007/s10156-010-0112-2
9. NJ Raymond DA Bremner 1995 The in vitro activity of biapenem against 964 clinical isolates of aerobic bacteria JAntimicrob Chemother 35 681 686 7592182 10.1093/jac/35.5.681 1:CAS:528:DyaK2MXmtVarurY%3D
10. M Fukazawa Y Sumita ET Harabe T Tanio H Nouda T Kohzuki, et al. 1992 Stability of meropenem and effect of1β-methyl substitution on its stability in the presence of renal dehydropeptidase I Antimicrob Agents Chemother 36 15771579 10.1128/AAC.36.7.1577
11. Y Yang RT Testa N Bhachech BA Rasmussen K Bush 1999 Biochemical characterization of novel tetrahydrofuranyl1β-methylcarbapenems: stability to hydrolysis by renal dehydropeptidases and bacterial β-lactamase, binding topenicillin binding proteins and permeability properties Antimicrob Agents Chemother 43 2904 2909 105828801:CAS:528:DyaK1MXnvVCqsbs%3D
12. T Takata K Aizawa A Shimizu S Sakakibara H Watabe K Totsuka 2004 Optimization of dose and dose regimen of biapenembased on pharmacokinetic and pharmacodynamic analysis J Infect Chemother 10 76 85 15160299 10.1007/s10156-003-0292-01:CAS:528:DC%2BD2cXktlahu7k%3D (Pubitemid 38590729)
13. Y Kaneko K Yanagihara M Kuroki H Ohi H Kakeya Y Miyazaki, et al. 2001 Effects of parenterally administeredciprofloxacin in a murine model of pulmonary Pseudomonas aeruginosa infection mimicking ventilator-associated pneumoniaChemotherapy 47 421 429 11786657 10.1159/000048553 1:CAS:528: DC%2BD38XhtF2hsrs%3D (Pubitemid 34062869)
14. Y Sumita H Nouda H Tada T Kohzuki M Kato T Okuda, et al. 1992 Pharmacokinetics of meropenem, a new carbapenemantibiotic, parenterally administered to laboratory animals Chemotherapy (Tokyo) 40 suppl 1 S123 S131
15. N Yamashita K Kawashima K Nomura H Takeuchi M Hikida T Naruke 1994 Pharmacokinetics of biapenem in laboratory animalsChemotherapy (Tokyo) 42 suppl 1 S243 S250
16. JP Iaconis DH Pitkin W Sheikh HL Nadler 1997 Comparison of antibacterial activities of meropenem and six otherantimicrobials against Pseudomonas aeruginosa isolates from North American studies and clinical trials Clin Infect Dis 24suppl 2 S191 S196 9126693 10.1093/clinids/24.Supplement-2.S191 1:CAS:528:DyaK2sXhtlOltLc%3D
17. JA Karlowsky DC Draghi ME Jones C Thornsberry TR Friedland DF Sahn 2003 Surveillance of antimicrobial susceptibilityamong clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the UnitedStates, 1998-2001 Antimicrob Agents Chemother 47 1681 1688 12709340 10.1128/AAC.47.5.1681-1688.20031:CAS:528:DC%2BD3sXjslGhtbk%3D (Pubitemid 36548554)
18. MD Zilberberg J Chen SH Mody AM Ramsey AF Shorr 2010 Imipenem resistance of Pseudomonas in pneumonia: a systemicliterature review BMC Pulm Med 10 45 20796312 10.1186/1471-2466-10-45
19. H Kropp JG Sundelof R Hajdu FM Kahan 1982 Matabolism of thienamycin and related carbapenem antibiotics by the renaldipeptidase, dehydropeptidase Antimicrob Agents Chemother 22 62 70 7125632 10.1128/AAC.22.1.62 1:CAS:528:DyaL38XltVersrw%3D(Pubitemid 12029995)
20. M Hikida K Kawashima M Yoshida S Mithuhashi 1992 Inactivation of new carbapenem antibiotics by dehydropeptidase-I fromporcine and human renal cortex J Antimicrob Chemother 30 129 134 1301069 10.1093/jac/30.2.129 1:CAS:528:DyaK38XmtVCntLc%3D
21. J Byers M Sole 2000 Analysis of factors related to the development of ventilator-associated pneumonia: use of existingdatabases Am J Crit Care 9 344 349 10976358 1:STN:280:DC%2BD3M7ivV2itg%3D%3D
22. WA Craig SC Ebert 1992 Continuous infusion of β-lactam antibiotics Antimicrob Agents Chemother 36 2577 25831482127 10.1128/AAC.36.12.2577 1:CAS:528:DyaK3sXjt1Chtg%3D%3D
23. K Sasaki T Arai 1994 In vitro postantibiotic effect of biapenem, a new carbapenem antibiotic Chemotherapy (Tokyo) 42108 114 1:CAS:528: DyaK2MXjt1yks7w%3D
24. Y Morinaga K Yanagihara S Nakamura K Yamamoto K Izumikawa M Seki, et al. 2008 In vivo efficacy and pharmacokinetics oftomopenem (CS-023), a novel carbapenem, against Pseudomonas aeruginosa in a murine chronic respiratory tract infection modelJ Antimicrob Chemother 62 1326 1331 18835805 10.1093/jac/dkn411 1:CAS:528:DC%2BD1cXhtl2gs7jN